Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human ALL Cell line RS4;11: Control vs. VE-465 treated

ABSTRACT: Transcriptional profiling of human acute lymphoblastic leukemia cell lines RS4;11: compare untreated RS4;11 with RS4;11 treated with VE-465. The goal was to determine the effects of VE-465 on global gene expression in RS4;11.

ORGANISM(S): Homo sapiens

PROVIDER: GSE42620 | GEO | 2012/11/30

SECONDARY ACCESSION(S): PRJNA182365

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Human ALL Cell line RS4;11: Control vs. VE-465 treated

Project description:Transcriptional profiling of human acute lymphoblastic leukemia cell lines RS4;11: compare untreated RS4;11 with RS4;11 treated with VE-465. The goal was to determine the effects of VE-465 on global gene expression in RS4;11. VE-465 induced gene expression in RS4;11 was measured at 48 hours after exposure to doses of 0 and 200 nM VE-465. Three independent experiments were performed.

2012-11-30 | E-GEOD-42620 | biostudies-arrayexpress

Homo sapiens

Project description:Human ALL Cell line RS4;11: Control vs. VE-465 treated

| PRJNA182365 | ENA

Nucleosome dynamics and gene expression in glucocorticoid-treated acute lymphoblastic leukemia, RS4;11

Project description:Nucleosome dynamics and gene expression in glucocorticoid-treated acute lymphoblastic leukemia, RS4;11

| PRJNA291621 | ENA

Mechanistic study of Wee1 kinase inhibition with AZD1775 exposes drug targetable vulnerabilities in acute B-lymphoblastic leukemia [GROseq]

Project description:Nascent transcription and enhancer activity was studied using GRO-seq in the acute lymphoblastic leukemia cell line RS4;11 upon inhibition of the WEE1 kinase.

2023-05-14 | GSE220099 | GEO

Mechanistic study of Wee1 kinase inhibition with AZD1775 exposes drug targetable vulnerabilities in acute B-lymphoblastic leukemia [scATAC-seq]

Project description:This study characterized the effect of WEE1 kinase inhibition using AZD1775 treatment on single-cell accessible chromatin and gene expression profile in the acute lymphoblastic leukemia cell line RS4;11 that represents the KMT2A-rearranged subtype.

2023-05-14 | GSE218805 | GEO

Bulk RNA sequencing of VE-Cadherin+GFP+, VE-Cadherin- GFP+ and VE-Cadherin+GFP- populations from E11.5 miR144/451+/GFP mouse yolk sac.

Project description:The aim of the experiment was to compare a newly defined population VE-Cadherin+GFP+ to control populations, VE-Cadherin- GFP+ and VE-Cadherin+GFP-.

2019-04-20 | GSE113403 | GEO

Mechanistic study of Wee1 kinase inhibition with AZD1775 exposes drug targetable vulnerabilities in acute B-lymphoblastic leukemia [scRNA-seq]

Project description:This study characterized the effect of WEE1 kinase inhibition using AZD1775 treatment on single-cell gene expression profile using the 10x Genomics protocol in the acute lymphoblastic leukemia cell lines RS4;11 (KMT2A-rearranged subtype) and Nalm6 (other subtype).

2023-05-14 | GSE218621 | GEO

Expression analysis of human pancreatic cancer cell lines (Capan-1, Panc-1, Panc-1+ve and Panc-1-ve) and pancreatic ductal cell line (HPDE)

Project description:Analysis of differentially expressing genes in whole genome wide analysis of aptamer SQ2 positive cells (Capan-1, Panc-1, Panc-1+ve) and SQ2 negative cells (Panc-1-ve and HPDE) Panc-1 +ve and Panc-1-ve cell lines were generated from Panc-1 cell line based upon its hetergenous binding to aptamer SQ2. Detailed procedure of generation of these cell lines are described in Pooja Dua, Hye Suk Kang, Seung-Mo Hong, Ming-Sound Tsao, Soyoun Kim, and Dong-ki Lee. 2012 Alkaline Phosphatase ALPPL2 is a novel pancreatic carcinoma-associated protein. Cancer Research

2012-11-21 | GSE42428 | GEO

Mechanistic study of Wee1 kinase inhibition with AZD1775 exposes drug targetable vulnerabilities in acute B-lymphoblastic leukemia [scMultiome]

Project description:This study characterized the effect of WEE1 kinase inhibition using AZD1775 treatment on single-cell accessible chromatin and gene expression profile using the 10x Genomics multiome protocol (ATAC + Gene Expression Assay) in the acute lymphoblastic leukemia cell line RS4;11 that represents the KMT2A-rearranged subtype.

2023-05-14 | GSE220112 | GEO

Expression data from glucocorticoid-treated acute lymphoblastic leukemia cell line, RS4;11

Project description:Precise nucleosome positioning is an increasingly recognized feature of promoters and enhancers, reflecting complex contributions of DNA sequence, nucleosome positioning, histone modification and transcription factor binding to enhancer activity and regulation of gene expression. Changes in nucleosome position and occupancy, histone variants and modifications, and chromatin remodeling are also critical elements of dynamic transcriptional regulation, but poorly understood at enhancers. We investigated glucocorticoid receptor-associated (GR) nucleosome dynamics at enhancers in acute lymphoblastic leukemia. For the first time, we demonstrate functionally distinct modes of nucleosome remodeling upon chromatin binding by GR, which we term central, non-central, phased, and minimal. Central and non-central remodeling reflect nucleosome eviction by GR and cofactors, respectively. Phased remodeling involves nucleosome repositioning and is associated with rapidly activated enhancers and induction of gene expression. Minimal remodeling sites initially have low levels of enhancerassociated histone modification, but the majority of these regions gain H3K4me2 or H3K27Ac to become de novo enhancers. Minimal remodeling regions are associated with gene ontologies specific to decreased B cell number and mTOR inhibition and may make unique contributions to glucocorticoid-induced leukemia cell death. Our findings form a novel framework for understanding the dynamic interplay between transcription factor binding, nucleosome remodeling, enhancer function, and gene expression in the leukemia response to glucocorticoids. We used microarrays to measure changes in gene expression following treatment of cells with dexamethasone for 0, 8, or 24 hours.

2015-10-01 | GSE71615 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data